Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a humanized IgG-2 monoclonal antibody that inhibits sclerostin, a mediator of bone remodeling. It decreases bone resorption and therefore increases bone mineralization. Indicated for patients with osteoporosis at high risk of fracture. Subcutaneous administration once a month for 12 months. Calcium and vitamin D supplements should be given during treatment.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its very high molecular weight make it highly unlikely that significant quantities will pass into breast milk.
Due to its protein nature, it is degraded in the gastrointestinal tract, and is not absorbed as such (virtually zero oral bioavailability), which makes it difficult or prevents its passage into infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period, in which there may be greater intestinal permeability.
Null or negligible passage into breast milk of similar monoclonal antibodies, such as adalimumab, belimumab, certolizumab, golimumab, infliximab, ipilimumab, natalizumab, rituximab, tocilizumab and ustekinumab has been confirmed.
No problems have been detected in infants whose mothers received other similar monoclonal antibodies such as belimumab, infliximab, rituximab, tocilizumab, or ustekinumab.
Expert authors consider that the use of monoclonal antibodies during breastfeeding is safe or very likely to be safe (Hale, Whittam 2019, Matro 2018, Anderson 2018 and 2016, Witzel 2014, Pistilli 2013).
Given the strong evidence that exists on the benefits of breastfeeding and the development of babies and the health of their mothers, it might be appropriate to evaluate the risk-benefit of any maternal treatment, including chemotherapy, and counsel individually each mother who wishes to continue breastfeeding (Koren 2013).
Monitor the possibility of hypocalcemia.